Merck Expands Biosafety Testing Lab in Singapore to Support Asia Pacific Biopharma Industry

Merck has expanded its biosafety testing laboratory in Singapore to further strengthen analytical and biosafety testing services for customers across the Asia Pacific region.

The expansion builds on Merck's global testing expertise of more than 75 years, which marks a significant milestone in providing advanced, local contract testing services for the region's growing biopharma industry.

Merck's Singapore laboratory will become the first BioReliance facility in Asia-Pacific to offer both Cell Line Characterisation services and GMP next-generation sequencing (NGS) capabilities, as well as advanced molecular methods including Blazar, a proprietary platform for rapid virus detection.